Mikhail Blagosklonny is one of the most notable members in the field of cancer research owing to the incredible contribution that he has made to the field. He has been in the field of cancer research since the start of his career and has made numerous noteworthy discoveries that have impacted the kind of treatment that patients who are diagnosed with cancer receive. At the beginning of his career, he started working at a research company known as Ordway, which focused on oncological research. The company was exactly what Mikhail Blagosklonny needed to be able to do what he wanted to do. He made numerous discoveries while working here, and contributed to the growth of the company immensely. He was regarded as an important member of the company owing to the impact that he had on it, and the field of oncology as a whole.His work with Rapamycin is by far one of the most notable discoveries that he Mikhail Blagosklonny has made in his career. The fact of the matter is that this revolutionary discovery that he made does not pertain to the field of oncology, but did stem from it.
While researching on the treatments that doctors were at the time offering to their patients, he discovered that Rapamycin was doing something completely different when given to the patients. This chemical was found in a majority of cancer treating drugs that patients had to take, and was seen to have properties that improved the life expectancy of those who were taking it. There is very little research out there about drugs that can achieve this, which is why Mikhail Blagosklonny is so highly regarded in the field of medicine and medical research.Teaching has always been one of Mikhail Blagosklonny’s passions, which is why soon after completing his degree in medicine, he went on to become a professor at the New York Medical College. At NYU, Mikhail Blagosklonny was a mentor to numerous students who were entering the field of medicine and medical research. He was considered to be one of the most proficient professors at the college and inspired numerous students to follow in his footsteps and enter the field of oncological research.
Today, Mikhail Blagosklonny is the head of the department at the Roswell Park Cancer Institute, where he imparts his knowledge to students who are entering the field of oncology and specializing in it. He uses his years worth of experience to educate these students and give them the knowledge that they wouldn’t get anywhere else. By teaching, he hopes to give rise to the new generation of researchers and scientist who have the drive and the motivation to find a cure to diseases that take away millions of lives every year.Mikhail Blagosklonny has also had numerous publications of his work. He is also the founder of Oncotarget, one of the largest peers to peer medical journals that are entirely focused on the field of oncology. The newsletter is published every week and is sent to all those who wish to read it and get to know more about the developments in the field of medicine.
Dr. Clay Siegall is globally recognized for his role in the cancer research community. He is the founder and CEO of Seattle Genetics. He has interests in targeted cancer therapies and drug development. Recently, Siegall achieved a remarkable milestone in his life when he led the company into developing antibody-drug conjugates (ADCs), which are used in cancer treatment. Dr. Siegall owns a blog on wordpress.com, the Clay Siegall blog.
Siegall keeps his followers updated on several issues ranging from scientific research, technology, and politics. He derives the information from the National Public Radio (NPR). In his recent posts, he posted news on Trump’s intention to ditch the 2015 clean power plan, which was signed in Paris. The agreement, which was signed by President Obama, aimed at reducing United State’s contribution to global warming.
Regarding scientific research, he posted an article concerning the breakthrough in the treatment of various problems such as endometriosis, fibroids and gynecologic cancer that affect the female reproductive system. This will be made real after scientists developed a device mimicking the human female reproductive system. Still, in the scientific research, he posted an article concerning a recently developed device that decodes human thoughts enabling paralyzed people to control their muscles.
About Clay Siegall
The Seattle Genetics boss is a zoology graduate from the University of Maryland. He is also a holder of a Ph.D. in genetics from the George Washington University. Over his career, he has received various awards for his tireless efforts in cancer treatment research. In 1995, he received the Pierce Award, and in 2002, he was given the Ernst and Young Entrepreneur Award of the Year of the Pacific Northwest.
Role in Cancer Research Community
Siegall’s role in cancer research cannot be underestimated. He is known for the development of ADCs, which are essential in cancer treatment. Moreover, he has devoted most of his time in research about a technology that can necessitate the monoclonal antibodies to deliver cell-killing agents to the cancerous cells.
Role at Seattle Genetics
Under his leadership, the company has achieved tremendous success. With over 20 years of experience in cancer research, Dr. Siegall has led the firm into several strategic licenses, which has seen the company raise over $ 300 million. Siegall also led the firm to various capital raising initiatives gaining over $675 million during the company’s first public offering.